Stratified by Baseline CV Risk Category Aspirin for Secondary Prevention of CV Disease Anticoagulant Therapy in CAD Warfarin WARIS2 ATLAS ACS 2 TIMI 51 Rivaroxaban vs Placebo After ACS COMPASS ID: 751807
Download Presentation The PPT/PDF document "CAD/PAD in Primary Care CV Risk in Stabl..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
CAD/PAD in Primary CareSlide2Slide3
CV Risk in Stable OutpatientsStratified by Baseline CV Risk CategorySlide4
Aspirin for Secondary Prevention of CV DiseaseSlide5
Anticoagulant Therapy in CAD
Warfarin -- WARIS-2Slide6
ATLAS ACS 2 -- TIMI 51
Rivaroxaban vs Placebo After ACSSlide7
COMPASSTrial DesignSlide8
COMPASSPrimary Efficacy Outcome -- CV Death/MI/StrokeSlide9
COMPASSCumulative Risk of CV Death/Stroke/MISlide10
COMPASSBleeding OutcomesSlide11
COMPASSCV Death and All-Cause DeathSlide12
COMPASS: CAD and PAD CohortsSlide13
COMPASS PAD CohortPeripheral Limb OutcomesSlide14
Potential Tolerability Concerns With Adding Rivaroxaban TherapySlide15
Managing Tolerability ConcernsSlide16
Strategies to Improve Persistence and Adherence to Rivaroxaban Therapy Slide17
Correct Dose of RivaroxabanSlide18
VOYAGER PADSlide19
PADScreening Recommendations Slide20
RivaroxabanFDA Approval: October 15, 2018Slide21
External Applicability of the COMPASS Trial
REACH RegistrySlide22
Managing Patients with Stable CAD/PAD in Primary CareSlide23
SummarySlide24